Dulaglutide vs Lixisenatide
Head-to-head comparison of Dulaglutide (Recombinant GLP-1 receptor agonist Fc fusion protein) and Lixisenatide (Exendin-4-derived GLP-1 receptor agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Dulaglutide | Lixisenatide |
|---|---|---|
| Category | Weight Management | Weight Management |
| Full Name | Recombinant GLP-1 receptor agonist Fc fusion protein | Exendin-4-derived GLP-1 receptor agonist |
| Molecular Weight | ~63,000 Da | 4858 Da |
| Half-Life | About 5 days | 2-4 hours |
| Amino Acids | N/A | 44 |
| Typical Dose | 0.75-4.5 mg weekly | 10-20 mcg daily |
| Route | Subcutaneous | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 700 | 400 |
| Research Status | Approved | Approved |
Dulaglutide Benefits
- ✓modest weight loss
- ✓lower A1c
- ✓weekly dosing convenience
- ✓cardiometabolic benefit
Lixisenatide Benefits
- ✓postprandial glucose control
- ✓modest weight loss
- ✓appetite reduction
- ✓short-acting option
Dulaglutide Dosing
0.75-4.5 mg SC weekly|Increase based on response and tolerance|Administer on the same day each week
Lixisenatide Dosing
10 mcg SC daily for 14 days|Increase to 20 mcg daily|Inject before the first meal of the day
Dulaglutide Side Effects
- ⚠nausea
- ⚠diarrhea
- ⚠injection-site reactions
Lixisenatide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠hypoglycemia when combined with insulin
Research Overview
Dulaglutide
Dulaglutide has repeatedly shown small-to-moderate reductions in body weight alongside glycemic improvement in large diabetes trials. It is a useful comparator for GLP-1 receptor agonist effects on appetite and weight.
Lixisenatide
Lixisenatide produces small but measurable weight loss in diabetes trials while improving postprandial glucose excursions. Its shorter half-life makes it a useful reference compound for first-generation incretin mimetics.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.